Tuesday, August 09, 2022 8:26:46 PM
Verona Pharma Announces Proposed Underwritten Public Offering Of 10M ADSs
4:42 pm ET August 9, 2022 (Benzinga) Print
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares ("ADSs"), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share (the "Offering"). All ADSs in the Offering will be offered by Verona Pharma. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. In addition, Verona Pharma intends to grant the underwriters of the Offering a 30-day option to purchase up to an additional 1.5 million ADSs at the public offering price, less the underwriting discount and commission.
4:42 pm ET August 9, 2022 (Benzinga) Print
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares ("ADSs"), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share (the "Offering"). All ADSs in the Offering will be offered by Verona Pharma. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. In addition, Verona Pharma intends to grant the underwriters of the Offering a 30-day option to purchase up to an additional 1.5 million ADSs at the public offering price, less the underwriting discount and commission.
New York Yankees and Duke Basketball
Recent VRNA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:45:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:43:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:41:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:40:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:35:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:32:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:31:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:30:17 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 10/07/2025 05:03:40 PM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 10/07/2025 04:59:34 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 10/07/2025 04:55:41 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 10/07/2025 12:56:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2025 11:03:44 AM
- Merck Completes Acquisition of Verona Pharma • Business Wire • 10/07/2025 10:45:00 AM
- Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales • GlobeNewswire Inc. • 10/06/2025 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2025 08:20:48 PM
- Shareholders of Verona Pharma Approve Proposed Acquisition by Merck • GlobeNewswire Inc. • 09/24/2025 08:05:00 PM
- Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025 • GlobeNewswire Inc. • 09/16/2025 10:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/10/2025 09:00:20 PM
